Drugs / SV-BR-1-GM
SV-BR-1-GM
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07199413 | Jun 2026 → Apr 2029 | malignant leptomeningeal tumor, metastatic malignant neoplasm in the brain | Medical College of Wisconsin | Withdrawn | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT04418219 | Dec 2020 → Jan 2023 | female breast carcinoma, invasive breast carcinoma | Thomas Jefferson University | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT03328026 | Mar 2018 → Mar 2026 | breast cancer | BriaCell Therapeutics Corporation | Completed | No outcome recorded |
| Phase 1/2 | NCT03066947 | May 2017 → Nov 2018 | breast cancer | BriaCell Therapeutics Corporation | Completed | No outcome recorded |
| Phase 1/2 | NCT00095862 | Nov 2004 → ? | breast cancer | Wiseman Research Initiatives LLC | Terminated | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06072612 | Dec 2023 → Dec 2027 expected | breast cancer | BriaCell Therapeutics Corporation | Recruiting | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SVBR- 1-GM | “SVBR- 1-GM Cell Line Genetically Engineered To Produce Granulocyte- Macrophage Colony Stimulating Factor” NCT00095862 ↗6“clinical formulations of SV-BR-1-GM, a GM-CSF-secreting breast tumor cell line” PMID 29867922 ↗ May 2018 |
| Known as | Breast Cancer Vaccine SV-BR-1-GM | “Breast Cancer Vaccine SV-BR-1-GM, Bria-IMT, GM-CSF Gene-transfected Breast Cancer Vaccine SV-BR-1-GM, SV-BR-1 Breast Cancer Cell Line Vaccine, SV-BR-1-GM, SV-BR-1-GM Vaccine” NCT04418219 ↗ |
| Known as | Bria-IMT | “Breast Cancer Vaccine SV-BR-1-GM, Bria-IMT, GM-CSF Gene-transfected Breast Cancer Vaccine SV-BR-1-GM, SV-BR-1 Breast Cancer Cell Line Vaccine, SV-BR-1-GM, SV-BR-1-GM Vaccine” NCT04418219 ↗ |
| Known as | GM-CSF Gene-transfected Breast Cancer Vaccine SV-BR-1-GM | “Breast Cancer Vaccine SV-BR-1-GM, Bria-IMT, GM-CSF Gene-transfected Breast Cancer Vaccine SV-BR-1-GM, SV-BR-1 Breast Cancer Cell Line Vaccine, SV-BR-1-GM, SV-BR-1-GM Vaccine” NCT04418219 ↗ |
| Known as | SV-BR-1 Breast Cancer Cell Line Vaccine | “Breast Cancer Vaccine SV-BR-1-GM, Bria-IMT, GM-CSF Gene-transfected Breast Cancer Vaccine SV-BR-1-GM, SV-BR-1 Breast Cancer Cell Line Vaccine, SV-BR-1-GM, SV-BR-1-GM Vaccine” NCT04418219 ↗ |
| Known as | SV-BR-1-GM Vaccine | “Breast Cancer Vaccine SV-BR-1-GM, Bria-IMT, GM-CSF Gene-transfected Breast Cancer Vaccine SV-BR-1-GM, SV-BR-1 Breast Cancer Cell Line Vaccine, SV-BR-1-GM, SV-BR-1-GM Vaccine” NCT04418219 ↗ |
| Modality | Vaccine | “tumor vaccine comprising HER2/neu-positive allogeneic (non-self) breast cancer cells transfected with the sargramostim (GM-CSF) gene” NCT00095862 ↗ |
| Route | Other | “tumor vaccine comprising HER2/neu-positive allogeneic (non-self) breast cancer cells transfected with the sargramostim (GM-CSF) gene intradermally (ID) on day 1” NCT00095862 ↗ |